Rituximab in ANCA-Associated Vasculitis

被引：41
|
作者：
Hassan, Romina I. [1 ]
Gaffo, Angelo L. [2 ,3 ]
机构：
[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina
[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA
[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期
关键词：
Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;
D O I：
10.1007/s11926-017-0632-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
    Miloslavsky, Eli
    Specks, Ulrich
    Merkel, Peter A.
    Seo, Philip
    Spiera, Robert F.
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    St Clair, E. William
    Tchao, Nadia
    Ding, Linna
    Ikle, David
    Jepson, Brett
    Brunetta, Paul
    Stone, John H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1190 - S1190
  • [22] Impact of rituximab trials on the treatment of ANCA-associated vasculitis
    Alberici, Federico
    Jayne, David R. W.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (06) : 1151 - 1159
  • [23] Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
    Guillevin, L.
    Pagnoux, C.
    Karras, A.
    Khouatra, C.
    Aumaitre, O.
    Cohen, P.
    Maurier, F.
    Decaux, O.
    Ninet, J.
    Gobert, P.
    Quemeneur, T.
    Blanchard-Delaunay, C.
    Godmer, P.
    Puechal, X.
    Carron, P. -L.
    Hatron, P. -Y.
    Limal, N.
    Hamidou, M.
    Ducret, M.
    Daugas, E.
    Papo, T.
    Bonnotte, B.
    Mahr, A.
    Ravaud, P.
    Mouthon, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19): : 1771 - 1780
  • [24] Rituximab for ANCA-associated vasculitis: The experience in the United States
    Clain, Jeremy M.
    Specks, Ulrich
    PRESSE MEDICALE, 2013, 42 (04): : 530 - 532
  • [25] Long-term rituximab for ANCA-associated vasculitis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (07): : E389 - E389
  • [26] Rituximab for ANCA-associated vasculitis in the setting of severe infection
    Gregersen, J. W.
    Chaudhry, A.
    Jayne, D. R. W.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (03) : 207 - 210
  • [27] Rituximab in ANCA-associated vasculitis (AAV), a case series
    Wendt, Marten
    Gunnarsson, Iva
    Bratt, Johan
    Bruchfeld, Annette
    APMIS, 2009, 117 : 80 - 80
  • [28] Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
    Stone, John H.
    Merkel, Peter A.
    Spiera, Robert
    Seo, Philip
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Clair, E. William St.
    Turkiewicz, Anthony
    Tchao, Nadia K.
    Webber, Lisa
    Ding, Linna
    Sejismundo, Lourdes P.
    Mieras, Kathleen
    Weitzenkamp, David
    Ikle, David
    Seyfert-Margolis, Vicki
    Mueller, Mark
    Brunetta, Paul
    Allen, Nancy B.
    Fervenza, Fernando C.
    Geetha, Duvuru
    Keogh, Karina A.
    Kissin, Eugene Y.
    Monach, Paul A.
    Peikert, Tobias
    Stegeman, Coen
    Ytterberg, Steven R.
    Specks, Ulrich
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03): : 221 - 232
  • [29] Maintenance rituximab treatment for ANCA-associated vasculitis: to be continued?
    Cheung, Chee Kay
    McAdoo, Stephen P.
    RHEUMATOLOGY, 2021, 60 (03) : 1010 - 1012
  • [30] ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
    van Dam, Laura
    Dirikgil, Ebru
    Bredewold, Edwin
    Ray, Argho
    Rabelink, Ton
    van Kooten, Cees
    Teng, Onno
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345